Compare EVGO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGO | LCTX |
|---|---|---|
| Founded | 2010 | 1990 |
| Country | United States | United States |
| Employees | 331 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.9M | 391.1M |
| IPO Year | N/A | 1996 |
| Metric | EVGO | LCTX |
|---|---|---|
| Price | $2.12 | $1.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $5.23 | ★ $5.33 |
| AVG Volume (30 Days) | ★ 4.6M | 1.0M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $16.45 | $109.40 |
| Revenue Next Year | $29.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $1.64 | $0.40 |
| 52 Week High | $5.18 | $2.09 |
| Indicator | EVGO | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 55.00 |
| Support Level | $1.64 | $1.56 |
| Resistance Level | $3.27 | $1.82 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 87.25 | 78.72 |
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.